

Please type a plus sign (+) inside this box →

**COPY OF PAPERS
ORIGINALLY FILED**

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form ~~PAFT-A~~ & ~~TRADEMARK~~ PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

| | |
|------------------------|--------------|
| Application Number | 09/682,667 |
| Filing Date | 10/04/01 |
| First Named Inventor | Hsueh et al. |
| Group Art Unit | 1642 |
| Examiner Name | N/A |
| Sheet | 1 |
| of | 3 |
| Attorney Docket Number | STAN-072CON |

RECEIVED
TECH CENTER 1600
MAR 1 2002
U.S. PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Documents | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--|--|---|
| | | Number Kind Code ² <i>(if known)</i> | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Documents | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
|--------------------|-----------------------|---|--|--|---|----------------|
| | | Office ⁴ Number ⁴ Kind Code ⁵ <i>(if known)</i> | | | | |
| SSH | | WO_93/11267 | Hickish et al. | 06/10/93 | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| SSH | | BOYD, JANICE M., ET AL., Bik, A Novel Death-Inducing Protein Shares A Distinct Sequence Motif With Bel-2 Family Proteins And Interacts With Viral And Cellular survival-Promoting Proteins," Oncogene (1995)Vol.11:1921-1928. | |
| | | CHOI, SUN SHIM, ET AL., "A Novel Bel-2 Related Gene, Bfl-1, Is Expressed In Stomach Cancer And Preferentially Expressed In Bone Marrow," Oncogene (1995) Vol.11:1693-1698. | |
| | | CHITTENDEN, THOMAS, ET AL., "Induction Of Apoptosis By The Bcl-2 Homologue Bak," Nature (April 1995) Vol.374:733-736. | |

| | | |
|------------------------------------|---|--|
| SSM | CHITTENDEN, THOMAS, ET AL., "A Conserved Domain In Bak, Distinct From BH1 And BH2, Mediates Cell Death And Protein Binding Functions," The EMBO Journal (1995) Vol.14. No. (22): 5589-5596. | |
| | GIBSON, LEONIE, ET AL., "Bcl-w, A Novel Member Of The Bcl-2 Family, Promotes Cell Survival," Oncogene (1996) Vol.13:665-675. | |
| | HSU, SHEAU YU ET AL. (November 1997), "Bok is a Pro-Apoptotic Bcl-2 Protein with Restricted Expression in Reproductive Tissues and Heterodimerizes with Selective Anti-Apoptotic Bcl-2 Family Members," Proc. Natl. Acad. Sci. USA, Vol.94:12401-12406. | |
| COPY OF PAPERS ORIGINALLY FILED | INOHARA, NAOHIRO, ET AL., "Harakiri, A Novel Regulator Of Cell Death, Encodes A Protein That Activates Apoptosis And Interacts Selectively With Survival-Promoting Proteins Bcl-2 and Bcl-X," The EMBO Journal (1997) Vol.16. No. (7):1686-1694. | |
| | KARSAN, ALY, ET AL., "Cloning Of A Human Bcl-2 Homologue: Inflammatory Cytokines Induce Human A1 In Cultured Endothelial Cells," Blood (April 15,1996) Vol.87. No. (8): 3089-3096. | |
| | KIEFER, MICHAEL C., ET AL., "Modulation Of Apoptosis By The Widely Distributed Bcl-2 Homologue Bak," Nature (April 1995) Vol.374:736-739. | |
| ✓ | KOZOPAS, KAREN M., ET AL., "MCL1, A Gene Expressed In Programmed Myeloid Differentiation, Has Sequence Similarity to BCL2," Proc. Natl. Acad. Sci. USA (April 1993) Vol.90:3516-3520. | |
| SSM | OLTVAI, ZN, MILLMAN CL, KORMSEYER SJ, "BCL-2 HETERODIMERIZES IN VIVO WITH A CONSERVED HOMOLOG, BAX, THAT ACCELERATES PROGRAMMED CELL DEATH", CELL 1993, AUG. 27;74(4):609-19 | |
| SSM | SIMONIAN, PHILIP ET AL. (September 13,1996), "Bax Can Antagonize Bcl-X During Etoposide and Cisplatin-Induces Cell Death Independently of Its Heterodimerization with Bcl-X _L ", The Journal of Biological Chemistry, Vol 271 (37):22764-22772 | |
| | TSUJIMOTO, YOSHIHIDE, ET AL., "Analysis Of The Structure, Transcripts, And Protein Products Of Bcl-2, The Gene Involved In Human Follicular Lymphoma," Proc. Natl. Acad. Sci. (July 1986) Vol.83:5214-5218. | |
| | WHITE, EILEEN, "Life, Death, And The Pursuit Of Apoptosis," Genes & Development (1996) Vol. 10:1-15. | |
| | YIN, XIAO-MING, ET AL., "BH1 and BH2 Domains Of Bcl-2 Are Required For Inhibition Of Apoptosis And Heterodimerization With Bax," Nature (May 1994) Vol. 369:321-323. | |
| | GenBank Accession No. L22475 (1993) | |
| | GenBank Accession No. L22474 (1993) | |
| | GenBank Accession No. L22473 (1993) | |
| | GenBank Accession No. U76376 (1997) | |
| | GenBank Accession No. U59747 (1996) | |
| | GenBank Accession No. U29680 (1996) | |
| ✓ | GenBank Accession No. U23765 (1995) | |
| | GenBank Accession No. U34584 (1995) | |



| | | |
|-----|--------------------------------|--------|
| DSM | GenBank Accession No. U16812 | (1995) |
| | GenBank Accession No. U27467 | (1995) |
| | GenBank Accession No. M1 3995 | (1986) |
| | GenBank Accession No. A22899 | (1993) |
| | GenBank Accession No. W77668 | (1996) |
| | GenBank Accession No. AA103989 | (1996) |

PATENT & TRADEMARK OFFICE

Examiner
Signature

Date
Considered

7/29/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**COPY OF PAPERS
ORIGINALLY FILED**